Cystic fibrosis: Studies with the oyster ciliary assay

Barbara H. Bowman, B. J. Lankford, M. Carol McNeely, Steven D. Carson, Don R. Barnett, Kåre Berg

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Bioassays using ciliary systems have detected a factor or factors in cystic fibrosis (CF) sera and tissue culture medium derived from CF cells. The typical shortcomings of an assay measuring biological activity have been studied, and the means to overcome the weaknesses of the oyster gill cilia assay have been established. The presence of the cystic fibrosis mucociliary inhibitor (CFMI) in experimental fractions may be determined by accepting data from only those assays in which authentic CF and normal (non‐CF) fractions give defined reactions, by measuring the reaction of each sample at least three times, and by examining each experimental sample at a protein concentration greater than the minimum established in this study. The relative concentrations of the CFMI present in the first steps of purification of serum and medium have been calculated in terms of units of inhibition. Generally, the units of inhibition present in serum and medium fractions from heterozygotes are close to one‐half of that in fractions from homozygous sources. Analogous fractions concentrated from a normal (non‐CF) source never inhibited mucociliary activity, even when tested at nearly 100 times the CF concentration. Ciliary assays utilizing oyster gills are essential for monitoring fractionation procedures aimed at purifying the CFMI, and have been shown to be capable and reliable enough to do so.

Original languageEnglish (US)
Pages (from-to)333-343
Number of pages11
JournalClinical Genetics
Volume12
Issue number6
DOIs
StatePublished - Dec 1977

Fingerprint

Ostreidae
Cystic Fibrosis
Biological Assay
Cilia
Heterozygote
Serum
Culture Media
ciliary dyskinesia factor
Proteins

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Bowman, B. H., Lankford, B. J., McNeely, M. C., Carson, S. D., Barnett, D. R., & Berg, K. (1977). Cystic fibrosis: Studies with the oyster ciliary assay. Clinical Genetics, 12(6), 333-343. https://doi.org/10.1111/j.1399-0004.1977.tb00952.x

Cystic fibrosis : Studies with the oyster ciliary assay. / Bowman, Barbara H.; Lankford, B. J.; McNeely, M. Carol; Carson, Steven D.; Barnett, Don R.; Berg, Kåre.

In: Clinical Genetics, Vol. 12, No. 6, 12.1977, p. 333-343.

Research output: Contribution to journalArticle

Bowman, BH, Lankford, BJ, McNeely, MC, Carson, SD, Barnett, DR & Berg, K 1977, 'Cystic fibrosis: Studies with the oyster ciliary assay', Clinical Genetics, vol. 12, no. 6, pp. 333-343. https://doi.org/10.1111/j.1399-0004.1977.tb00952.x
Bowman, Barbara H. ; Lankford, B. J. ; McNeely, M. Carol ; Carson, Steven D. ; Barnett, Don R. ; Berg, Kåre. / Cystic fibrosis : Studies with the oyster ciliary assay. In: Clinical Genetics. 1977 ; Vol. 12, No. 6. pp. 333-343.
@article{b6004417d95e46dfa6243d568ce8e2db,
title = "Cystic fibrosis: Studies with the oyster ciliary assay",
abstract = "Bioassays using ciliary systems have detected a factor or factors in cystic fibrosis (CF) sera and tissue culture medium derived from CF cells. The typical shortcomings of an assay measuring biological activity have been studied, and the means to overcome the weaknesses of the oyster gill cilia assay have been established. The presence of the cystic fibrosis mucociliary inhibitor (CFMI) in experimental fractions may be determined by accepting data from only those assays in which authentic CF and normal (non‐CF) fractions give defined reactions, by measuring the reaction of each sample at least three times, and by examining each experimental sample at a protein concentration greater than the minimum established in this study. The relative concentrations of the CFMI present in the first steps of purification of serum and medium have been calculated in terms of units of inhibition. Generally, the units of inhibition present in serum and medium fractions from heterozygotes are close to one‐half of that in fractions from homozygous sources. Analogous fractions concentrated from a normal (non‐CF) source never inhibited mucociliary activity, even when tested at nearly 100 times the CF concentration. Ciliary assays utilizing oyster gills are essential for monitoring fractionation procedures aimed at purifying the CFMI, and have been shown to be capable and reliable enough to do so.",
author = "Bowman, {Barbara H.} and Lankford, {B. J.} and McNeely, {M. Carol} and Carson, {Steven D.} and Barnett, {Don R.} and K{\aa}re Berg",
year = "1977",
month = "12",
doi = "10.1111/j.1399-0004.1977.tb00952.x",
language = "English (US)",
volume = "12",
pages = "333--343",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Cystic fibrosis

T2 - Studies with the oyster ciliary assay

AU - Bowman, Barbara H.

AU - Lankford, B. J.

AU - McNeely, M. Carol

AU - Carson, Steven D.

AU - Barnett, Don R.

AU - Berg, Kåre

PY - 1977/12

Y1 - 1977/12

N2 - Bioassays using ciliary systems have detected a factor or factors in cystic fibrosis (CF) sera and tissue culture medium derived from CF cells. The typical shortcomings of an assay measuring biological activity have been studied, and the means to overcome the weaknesses of the oyster gill cilia assay have been established. The presence of the cystic fibrosis mucociliary inhibitor (CFMI) in experimental fractions may be determined by accepting data from only those assays in which authentic CF and normal (non‐CF) fractions give defined reactions, by measuring the reaction of each sample at least three times, and by examining each experimental sample at a protein concentration greater than the minimum established in this study. The relative concentrations of the CFMI present in the first steps of purification of serum and medium have been calculated in terms of units of inhibition. Generally, the units of inhibition present in serum and medium fractions from heterozygotes are close to one‐half of that in fractions from homozygous sources. Analogous fractions concentrated from a normal (non‐CF) source never inhibited mucociliary activity, even when tested at nearly 100 times the CF concentration. Ciliary assays utilizing oyster gills are essential for monitoring fractionation procedures aimed at purifying the CFMI, and have been shown to be capable and reliable enough to do so.

AB - Bioassays using ciliary systems have detected a factor or factors in cystic fibrosis (CF) sera and tissue culture medium derived from CF cells. The typical shortcomings of an assay measuring biological activity have been studied, and the means to overcome the weaknesses of the oyster gill cilia assay have been established. The presence of the cystic fibrosis mucociliary inhibitor (CFMI) in experimental fractions may be determined by accepting data from only those assays in which authentic CF and normal (non‐CF) fractions give defined reactions, by measuring the reaction of each sample at least three times, and by examining each experimental sample at a protein concentration greater than the minimum established in this study. The relative concentrations of the CFMI present in the first steps of purification of serum and medium have been calculated in terms of units of inhibition. Generally, the units of inhibition present in serum and medium fractions from heterozygotes are close to one‐half of that in fractions from homozygous sources. Analogous fractions concentrated from a normal (non‐CF) source never inhibited mucociliary activity, even when tested at nearly 100 times the CF concentration. Ciliary assays utilizing oyster gills are essential for monitoring fractionation procedures aimed at purifying the CFMI, and have been shown to be capable and reliable enough to do so.

UR - http://www.scopus.com/inward/record.url?scp=0017663083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017663083&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0004.1977.tb00952.x

DO - 10.1111/j.1399-0004.1977.tb00952.x

M3 - Article

C2 - 589856

AN - SCOPUS:0017663083

VL - 12

SP - 333

EP - 343

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 6

ER -